Exclusive: Nanobiomedicine

Current status and prospect of cancer nanomedicine in clinical translation

  • LIU Jing ,
  • TANG Hao ,
  • MI Peng ,
  • WEI Yuquan
  • State Key Laboratory of Biotherapy;West China Hospital, Sichuan University, Chengdu 610041, China

Received date: 2018-09-12

  Revised date: 2018-10-12

  Online published: 2018-12-14


Nanomedicine has emerged to be a promising platform for cancer treatment with reduced side effect and increased therapeutic effect. In recent decades, with the advances in nanobiotechnology, much progress has been achieved in the development and clinical translation of cancer nanomedicines. Until now, several types of nanomedicines have been approved for cancer treatment in clinical and more candidates are in clinical trial. However, it is still a challenge for nanomedicines to treat tumors due to the complexity and heterogeneity nature of tumors. Herein, we summarize the current status and progress of cancer nanomedicines in clinical translation as well as discuss the challenge and future perspective.

Cite this article

LIU Jing , TANG Hao , MI Peng , WEI Yuquan . Current status and prospect of cancer nanomedicine in clinical translation[J]. Science & Technology Review, 2018 , 36(22) : 118 -126 . DOI: 10.3981/j.issn.1000-7857.2018.22.010


[1] Wilhelm S, Tavares A J, Dai Q, et al. Analysis of nanoparticle delivery to tumours[J]. Nature Review Materials, 2016, 1(5):16014.
[2] Kim B Y S, Rutka J T, Chan W C W. Nanomedicine[J]. New England Journal of Medicine, 2010, 363(25):2434-2443.
[3] Petros R A, DeSimone J M. Strategies in the design of nanoparticles for therapeutic applications[J]. Nature Reviews Drug Discovery, 2010, 9(8):615-627.
[4] Allen T M, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system[J]. Febs Letters, 1987, 223(1):42-46.
[5] Bangham A D, Standish M M, Watkins J C. Diffusion of univalent ions across the lamellae of swollen phospholipids[J]. Journal of Molecular Biology, 1965, 13(1):238.
[6] Langer R, Folkman J. Polymers for sustained-release of proteins and other macromolecules[J]. Nature, 1976, 263(5580):797-800.
[7] Yatvin M B, Kreutz W, Horwitz B A, et al. pH-sensitive liposomes:possible clinical implications[J]. Science, 1980, 210(4475):1253-1255.
[8] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy:Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J]. Cancer Research, 1986, 46(12 Part 1):6387-6392.
[9] Barenholz Y. Doxil®-The first FDA-approved nano-drug:Lessons learned[J]. Journal of Controlled Release, 2012, 160(2):117-134.
[10] Ragelle H, Danhier F, Préat V, et al. Nanoparticle-based drug delivery systems:A commercial and regulatory outlook as the field matures[J]. Expert Opinion on Drug Delivery, 2016, 14(7):851.
[11] Danhier F. To exploit the tumor microenvironment:Since the EPR effect fails in the clinic, what is the future of nanomedicine[J]. Journal of Controlled Release, 2016, 244(Pt A):108-121.
[12] Al-Jamal W T, Kostarelos K. Liposomes:From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine[J]. Accounts of Chemical Research, 2011, 44(10):1094-1104.
[13] Yi Y, Lin G, Chen S, et al. Polyester micelles for drug delivery and cancer theranostics:Current achievements, progresses and future perspectives[J]. Materials Science & Engineering C-Materials for Biological Applications, 2018, 83:218-232.
[14] Mi P, Wang F, Nishiyama N, et al. Molecular cancer imaging with polymeric nanoassemblies:From tumor detection to theranostics[J]. Macromolecular Bioscience, 2016, 17(1):1600305.
[15] Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery:Design, characterization and biological significance[J]. Advanced Drug Delivery Review, 2001, 47(1):113-131.
[16] Tibbitt M W, Dahlman J E, Langer R. Emerging frontiers in drug delivery[J]. Journal of the American Chemical Society, 2016, 138(3):704-717.
[17] Duncan R. Polymer conjugates as anticancer nanomedicines[J]. Nature Reviews Cancer, 2006, 6(9):688-701.
[18] Sparreboom A, Scripture C D, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)[J]. Clinical Cancer Research, 2005, 11(11):4136-4143.
[19] Wibroe P P, Ahmadvand D, Oghabian M A, et al. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, Doxorubicin, and SinaDoxosome[J]. Journal of Controlled Release, 2016, 221:1-8.
[20] Chen B, Li Y, Zhang X, et al. An efficient synthesis of ferumoxytol induced by alternating-current magnetic field[J]. Materials Letters, 2016, 170:93-96.
[21] Ma K, Sai H, Wiesner U. Ultrasmall sub-10 nm near-infrared fluorescent mesoporous silica nanoparticles[J]. Journal of the American Chemical Society, 2012, 134(32):13180-13183.
[22] Moran C H, Wainerdi S M, Cherukuri T K, et al. Size-dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields[J]. Nano Research, 2009, 2(5):400-405.
[23] Pirollo K F, Chang E H. Does a targeting ligand influence nanoparticle tumor localization or uptake?[J]. Trends in Biotechnology, 2008, 26(10):552-558.
[24] Jain R K. Delivery of molecular and cellular medicine to solid tumors[J]. Advanced Drug Delivery Reviews, 2001, 46(1):149-168.
[25] Verma A, Uzun O, Hu Y, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles[J]. Nature Materials, 2008, 7:588-595.
[26] Hrkach J, Von Hoff D, Ali M M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile[J]. Science Translational Medicine, 2012, doi:10.11261scitranslmed.3003651.
[27] Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded antiEGFR immunoliposomes in advanced solid tumours:A phase 1 dose-escalation study[J]. The Lancet Oncology, 2012, 13(12):1234-1241.
[28] Stylianopoulos T, Jain R K. Design considerations for nanotherapeutics in oncology[J]. Nanomedicine Nanotechnology Biology & Medicine, 2015, 11(8):1893-1907.
[29] Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer[J]. Annals of Oncology, 2004, 15(3):517-525.
[30] Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts[J]. Cancer Science, 2010, 95(7):608-613.
[31] Von Hoff, D D, Mita M M, Ramanathan R K, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors[J]. Clinical Cancer Research, 2016, 22(13):3157.
[32] Zuckerman J E, Gritli I, Tolcher A, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA[J]. PNAS, 2014, 111(31):11449-11454.
[33] Draz M S, Fang B A, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections[J]. Theranostics, 2014, 4(9):872-92.
[34] Alexis F, Pridgen E, Molnar L K, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles[J]. Molecular Pharmaceutics, 2008, 5(4):505-515.
[35] Perrault S D, Walkey C, Jennings T, et al. Mediating tumor targeting efficiency of nanoparticles through design[J]. Nano Letters, 2009, 9(5):1909-1915.
[36] Gu F, Zhang L, Teply B A, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers[J]. PNAS, 2008, 105(7):2586-2591.
[37] Nel A E, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface[J]. Nature Materials, 2009, 8(7):543-557.
[38] Alizadeh A A, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity[J]. Nature Medicine, 2015, 21(8):846-853.
[39] Junttila M R, Sauvage F J D. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467):346-354.
[40] Toh Y C, Lim T C, Tai D, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing[J]. Lab on A Chip, 2009, 9(14):2026.
[41] Huh D, Matthews B D, Mammoto A, et al. Reconstituting organ-level lung functions on a chip[J]. Science, 2010, 328(5986):1662.
[42] Albanese A, Lam A K, Sykes E A, et al. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport[J]. Nature Communication, 2013, 4(10):2718.
[43] Choi S Y, Lin D, Gout P W, et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer[J]. Advanced Drug Delivery Reviews, 2014, 80:222-237.
[44] Sharpless N E, Depinho R A. The mighty mouse:Genetically engineered mouse models in cancer drug development[J]. Nature reviews Drug discovery, 2006, 5(9):741-754.
[45] Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology:The impact of passive and active targeting in the era of modern cancer biology[J]. Advanced Drug Deliver Reviews, 2014, 66(24):2-25.
[46] Lin D, Wyatt A W, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development[J]. Cancer Research, 2014, 74(4):1272.
[47] Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model[J]. Nature Biotechnology, 2014, 32(4):364.
[48] Hubbard G K, Mutton L N, Khalili M, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer[J]. Cancer Research, 2016, 76(2):283.